my clinic, I clear the inflammatory lesions prior to starting treatment
with brimonidine gel. Some physicians report that they treat symptoms concomitantly with a successful outcome.
In conclusion, initiating a more tailored approach for the treatment
of specific symptoms rather than subtypes can help to ensure we provide the best results for our patients. Newly approved treatments, such as ivermectin 1% cream for the treatment of inflammatory lesions and brimonidine gel for the treatment of persistent erythema, will further strengthen the current armamentarium for this chronic disease.
DISCLOSURES
Dr. Stein Gold is an investigator for Galderma, Allergan, and Actavis, and an advisor for Galderma, Allergan, Valeant, Merz, and Actavis. Medical writing support was provided by Natasha Singh Kent PhD, Havas Life Medicom, and was funded by Galderma.
REFERENCES
- Baldwin H. Psychosocial implications of rosacea. The Dermatologist.2012;Supplement:2-4.
- Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
- Reinholz M, Tietze JK, Kilian K, et al. Rosacea S1 Guideline.JDDG.2013;11(8):768-780.
- Buhl T, Sulk M, Nowak P, et al. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea reveals Activation of Th1/Th17 Pathways. J Inv Dermatol. 2015; In press
- van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2011(3):CD003262.
- Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802.
- Oracea® Prescribing Information. Available at: http://www.galdermausa.com/PI/OraceaPI.pdf. Accessed 1 April 2015.
- Soolantra® Prescribing Information. Available at: http://www.galdermausa.com/pi/soolantrapi.pdf. Accessed 1 April 2015.
- Stein Gold L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316-23.
- Stein Gold L, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13(11):1380-6.
- Taieb A, Ortonne JP, et al; Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial Br J Dermatol. 2015;172:1103-1100.
- Galderma Laboratories LP. Mirvaso® (brimonidine) 0.33% topical gel package insert. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204708lbl.pdf.
- Fowler J, Jr., Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-6.
- Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-labeled study. J Drugs Dermatol 2014;13(1):56-61.
- Tanghetti EA, Jackson JM, Belasco KT, et al. Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2015;14(1):33-40.
